A detailed history of Susquehanna International Group, LLP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 32,869 shares of DYN stock, worth $933,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,869
Previous 25,521 28.79%
Holding current value
$933,150
Previous $900,000 31.11%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$31.94 - $47.04 $234,695 - $345,649
7,348 Added 28.79%
32,869 $1.18 Million
Q2 2024

Aug 15, 2024

SELL
$23.65 - $35.63 $9.82 Million - $14.8 Million
-415,013 Reduced 94.21%
25,521 $900,000
Q1 2024

May 07, 2024

BUY
$13.06 - $29.18 $5.41 Million - $12.1 Million
414,516 Added 1593.19%
440,534 $12.5 Million
Q4 2023

Feb 14, 2024

SELL
$6.62 - $13.64 $317,958 - $655,129
-48,030 Reduced 64.86%
26,018 $346,000
Q3 2023

Nov 14, 2023

BUY
$8.6 - $12.18 $456,152 - $646,039
53,041 Added 252.49%
74,048 $663,000
Q2 2023

Aug 11, 2023

SELL
$8.53 - $14.28 $251,686 - $421,345
-29,506 Reduced 58.41%
21,007 $236,000
Q1 2023

May 16, 2023

BUY
$10.88 - $15.0 $364,360 - $502,335
33,489 Added 196.72%
50,513 $581,000
Q4 2022

Feb 14, 2023

SELL
$9.37 - $13.8 $90,204 - $132,852
-9,627 Reduced 36.12%
17,024 $197,000
Q3 2022

Nov 14, 2022

BUY
$7.2 - $15.17 $191,887 - $404,295
26,651 New
26,651 $338,000
Q2 2021

Aug 11, 2021

SELL
$15.94 - $22.33 $234,031 - $327,849
-14,682 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$14.0 - $29.3 $205,548 - $430,182
14,682 New
14,682 $228,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.47B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.